Related references
Note: Only part of the references are listed.p38 MAPK Signaling Mediates Mitochondrial Apoptosis in Cancer Cells Induced by Oleanolic Acid
Jia Liu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells
Zi-Xiang Cong et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway
Jia Liu et al.
MARINE DRUGS (2014)
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme
Tor-Christian Aase Johannessen et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
NRF2, cancer and calorie restriction
A. Martin-Montalvo et al.
ONCOGENE (2011)
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
Jennifer A. Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
MGMT hypermethylation: A prognostic foe, a predictive friend
Filipe V. Jacinto et al.
DNA REPAIR (2007)
Glycogen synthase kinase-3β inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2
Maria Salazar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Modulation of chemotherapy resistance in regional therapy:: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine
T Ueno et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide
Y Hirose et al.
JOURNAL OF NEUROSURGERY (2004)
Share Paper
